Makers Laboratories Ltd Upgraded to Sell on Technical Improvements and Mixed Fundamentals

Quality Assessment: Weak Long-Term Fundamentals Persist

Makers Laboratories Ltd operates within the Pharmaceuticals & Biotechnology sector, an industry known for its volatility and regulatory challenges. The company’s quality rating remains subdued due to its weak long-term financial performance. Over the past five years, the firm has experienced a negative compound annual growth rate (CAGR) of -15.78% in operating profits, signalling deteriorating operational efficiency and profitability pressures.

Return on Equity (ROE), a key measure of profitability relative to shareholder funds, has averaged a mere 2.20%, indicating low returns on invested capital. In the most recent period, ROE has dropped to approximately zero, underscoring the company’s struggle to generate shareholder value. These metrics highlight persistent structural issues that weigh heavily on the company’s quality grade.

Valuation: Elevated Price to Book Ratio Raises Concerns

Despite the weak fundamentals, Makers Laboratories is trading at a premium valuation. The Price to Book (P/B) ratio stands at 1.3, which is considered expensive relative to its historical averages and peer group valuations. This premium valuation is difficult to justify given the company’s subdued profitability and declining profit trends.

Over the past year, the stock has delivered a modest return of 5.69%, yet profits have plummeted by 82.7%, reflecting a disconnect between market pricing and underlying earnings performance. Investors should be wary of this valuation gap, which may expose the stock to downside risk if earnings fail to recover.

Financial Trend: Mixed Signals from Recent Quarterly Results

On the financial front, Makers Laboratories reported encouraging results for Q3 FY25-26, which have contributed to the recent upgrade in rating. Profit Before Tax excluding other income (PBT LESS OI) surged to ₹2.82 crores, marking a robust growth of 152.9% compared to the previous four-quarter average. Net sales reached a record high of ₹35.67 crores, while Profit Before Depreciation, Interest and Tax (PBDIT) also hit a peak at ₹4.16 crores.

These positive quarterly results suggest a potential turnaround in operational performance, providing some relief to investors. However, the broader financial trend remains weak, as evidenced by the negative five-year CAGR and low ROE, which temper enthusiasm for a sustained recovery.

Technical Analysis: Upgrade Driven by Improved Market Indicators

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators, signalling a shift from a mildly bearish to a sideways trend. This technical transition reflects a stabilisation in the stock price after a period of decline, supported by several key metrics.

On a weekly basis, the Moving Average Convergence Divergence (MACD) indicator has turned bullish, while the monthly MACD remains bearish, suggesting mixed momentum but with short-term strength. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating neither overbought nor oversold conditions.

Bollinger Bands are bullish on both weekly and monthly timeframes, implying increased price volatility with an upward bias. Daily moving averages remain mildly bearish, reflecting some caution in the short term. The Know Sure Thing (KST) indicator is mildly bullish weekly but bearish monthly, while Dow Theory assessments are mildly bullish on both weekly and monthly charts.

Overall, these technical signals suggest that while the stock is not yet in a strong uptrend, the downward momentum has eased, and sideways consolidation is underway. This technical improvement has been a key factor in the rating upgrade, as it may provide a platform for potential price appreciation.

Stock Performance Relative to Sensex

Makers Laboratories has outperformed the Sensex over several recent periods, reflecting some resilience despite fundamental challenges. The stock returned 7.01% over the past week compared to a 1.74% decline in the Sensex. Over one month, the stock surged 28.46%, vastly outperforming the Sensex’s 0.91% gain. Year-to-date returns stand at 33.73%, while the Sensex has declined by 3.46% in the same period.

However, over longer horizons, the stock’s performance is less impressive. Over five years, Makers Laboratories has declined by 41.88%, while the Sensex gained 61.20%. Over ten years, the stock returned 158.80%, lagging behind the Sensex’s 258.10% gain. These figures highlight the stock’s volatility and the importance of monitoring both short-term momentum and long-term fundamentals.

Ownership and Market Capitalisation

The company’s majority shareholders are promoters, which often provides stability in management and strategic direction. Makers Laboratories holds a Market Cap Grade of 4, indicating a mid-sized market capitalisation within its sector. The current stock price is ₹158.00, up 11.98% on the day, with a 52-week high of ₹173.70 and a low of ₹109.00, reflecting recent volatility but also upward momentum.

Conclusion: Cautious Optimism Amidst Structural Challenges

The upgrade of Makers Laboratories Ltd’s investment rating from Strong Sell to Sell reflects a nuanced view of the company’s prospects. While technical indicators have improved significantly, signalling a potential stabilisation in share price, the company’s weak long-term fundamentals and expensive valuation remain key concerns.

Investors should weigh the recent positive quarterly financial results and technical momentum against the backdrop of declining profitability, low ROE, and valuation premiums. The stock’s relative outperformance in the short term versus the Sensex is encouraging but does not fully offset the structural challenges faced by the company.

For those considering exposure to Makers Laboratories, a cautious approach is warranted, with close attention to upcoming earnings releases and technical developments. The current Sell rating suggests that while the stock may no longer be a strong sell, it still carries significant risks that investors must carefully evaluate.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →